Hemophilia A and B market at $6.9B in 2018 in the 8MM and expects the market to increase to $9.3B in 2028 at a (CAGR) of 2.9%

HTF MI broadcasted a new title “Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028” with 228 pages and in-depth assessment including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players such as Alnylam Pharmaceuticals, Alveron Pharma, Aprilbio, Aptevo Therapeutics, Bakusuaruta, Baxalta, Baxter, Bayer, Beijing Tiantan Biological Products, Biogen, BioMarin, BioReliance etc. The research study provides forecasts for Hemophilia A and B - Drug Forecast and investments till 2024. The study also helps with cost structure benchmarking collectively derive after analyzing a vast coverage of industry players which is further compared with overall sector for each component such as Avg. Profit, Wages, Purchases, Depreciation, Marketing, Rent & utilities, Others etc.

Get Free Access to Sample Pages @ https://www.htfmarketreport.com/sample-report/2257073-hemophilia-a-and-b-global-drug-forecast-and-market

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028
Summary
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care.

Read Detailed Index of full Research Study at @ https://www.htfmarketreport.com/reports/2257073-hemophilia-a-and-b-global-drug-forecast-and-market

GlobalData projects the global hemophilia A and B marketplace to experience a significant growth during the forecast period. GlobalData valued the hemophilia A and B market at $6.9B in 2018 in the 8MM and expects the market to increase to $9.3B in 2028 at a Compound Annual Growth Rate (CAGR) of 2.9%. This growth will be driven primarily by the increasing prophylactic treatment rates among patients, the continued use of recombinant products and the uptake of non-replacement therapies in the 8MM. However, cost constraints in the 8MM are expected to limit the premium pricing opportunities for new products such as late-to-market long-acting factor concentrates and new alternative coagulation promoters, thereby limiting the size of the hemophilia market.

This model covers the market forecast for marketed and late-stage pipeline hemophilia A and B therapeutics. The base year of this model is 2018, and the forecast period is 2018-2028.
Key Questions Answered
- Which pipeline agents - replacement factors, alternative coagulation promoters and gene therapies - are the most promising and expected to launch in the 8MM
- What are the forecasted sales of these agents and what will be their impact in the hemophilia A and B market
- What are the main unmet needs in hemophilia A and B, and which pipeline drugs will fulfil these needs, and to what extent
- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy
- Key Opinions Leader (KOL) and payer insights across the 8MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.

Key Highlights
- The hemophilia A & B market is expected to grow at a CAGR of 2.9% until 2028, reaching a global value of $9.3B.
- GlobalData forecasts a marginal increase in prevalence rates across 8MM with AGR of 0.1% due to increased in prevalence rates across the US, Spain and UK.
- Gene therapies will emerge as novel treatments for hemophilia A & B during the forecast period. Particularly, BioMarin’s first-to-market gene therapy, ValRox is likely to perform exceptionally well. Additionally, Roche’s Hemlibra is anticipated to achieve blockbuster status by the end of the forecast period.
- Rising life expectancy for hemophilia patients leads to an increase in the size of the treated population.
- Expected launches of expensive new drugs such as gene therapies, continued preference for prophylactic regimens, continued patient evolution from plasma-based to recombinant therapies are other significant drivers of market.
- Limited scope for price premiums of late-to-market replacement products, high uptake of lower-priced drugs, rise in cost-consciousness and imposing market access barriers for the entry of expensive gene therapies are expected to affect market growth negatively.
- Level of unmet needs in hemophilia patients is high but is expected to decrease due to advances in treatments and the introduction of novel therapies.
- There are major market opportunities for the development of novel therapies, cheaper therapies for prophylaxis treatment, more effective treatments for hemophilia B patients with inhibitors and more therapies with convenient administration routes.
Scope

Overview of hemophilia A and B, including -
- Disease overview - etiology, pathophysiology, symptoms, prognosis and quality of life
- Epidemiology
- Disease management - diagnosis and treatment
Patient segmentation -
- Mild, Moderate, and Severe
- Hemophilia A and B with and without inhibitors
- Males and Females
- All ages, Pediatrics and Adults
Annualized hemophilia A and B therapeutics market revenue and treatment usage patterns -
- Patient shares and number of patients treated for marketed and pipeline products
- Duration of and, daily and annual cost of therapies per patient
- Product sales by usage and total sales of marketed and pipeline products

Enquire for customization in Report @ https://www.htfmarketreport.com/enquiry-before-buy/2257073-hemophilia-a-and-b-global-drug-forecast-and-market

Key topics covered include -
- Competitive assessment of marketed and pipeline products including SWOTs and, clinical and commercial positioning.
- Unmet needs and opportunities including current and future level of attainment and gap analysis
- Pipeline assessment - analysis of commercial and clinical attributes of promising drugs in clinical development and comprehensive analysis of promising approaches and emerging trends in early stage development
- Analysis of the current and future players for the global hemophilia A and B market, including strength of marketed and pipeline products and trends in corporate strategy, profiles of leading companies in the hemophilia market.
- Market outlook of the 8MM including forecast, key events and, market drivers and barriers.
Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned in the Report
Alnylam Pharmaceuticals
Alveron Pharma
Aprilbio
Aptevo Therapeutics
Bakusuaruta
Baxalta
Baxter
Bayer
Beijing Tiantan Biological Products
Biogen
BioMarin
BioReliance
Biotest
Bioverativ
Cangene Corporation
Catalyst Biosciences
The Chemo-Sero-Therapeutic Research Institute
China Biologic Products
Chengdu Rongsheng Pharmaceutical
Chugai Pharmaceutical
CSL Behring
Emergent BioSolutions
EpiVax
F. Hoffmann-La Roche
Freeline Therapeutics
GC Pharma
Genentech
Genetics Institute
Grifols
Hualan Biological Engineering
Idogen
Immuno
Ioproducts Laboratory
Japan Blood Products Organization
Kaifeng Pharmaceutical
Kedrion
Kymab
Laboratoire Français de Fractionnement et de Biotechnologies (LFB)
Novo Nordisk
Octapharma
Okklo Life Sciences
OPKO Biologics
Pfizer
Pharming Group
RegenxBio
Sanofi
Sangamo Therapeutics
Sanquin Pharmaceutical Services
Selecta Biosciences
Shanghai Baxter Healthcare
Shenzhen Geno-Immune Medical Institute
Shenzhen Weiwu Guangming Biological Preparations
Shire
SK Chemicals
Spark Therapeutics
St. Jude Children's Research Hospital
Swedish Orphan Biovitrum (SOBI)
Takeda Pharmaceutical
Ultragenyx Pharmaceutical
UniQure
Wyeth

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at LinkedIn | Facebook | Twitter

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

This release was published on openPR.